Search Results

web-platform for pharmacogenomics research Trinh Trung Duong Nguyen ,  Ziaurrehman Tanoli ,  Saad Hassan , Umut Onur Özcan ,   Jimmy Caroli ,   Albert J Kooistra ,   David E Gloriam ,   Alexander S Hauser GPCRdb Schedule a session with our Chief Match Maker. Direct line to the Dr. 🕵️‍♂️We'll soon be unveiling our University CheatSheet! Major Announcement! This will support our operations and community growth.

🔔 Subscribe to our monthly newsletter for FREE! ➡️ https://bit.ly/3cCI4em #gpcr #drgpcr

Drug discovery does not move in fixed conclusions. As datasets expand and systems are tested under new conditions, interpretations often require adjustment. What initially appears mechanistically clear can become more nuanced when additional experiments are layered in. Terry’s Pharmacology Corner is built around that reality. It is designed as a continuous learning environment — supporting scientific reasoning as programs mature, rather than treating pharmacology as a one-time lesson. The analysis below emerged from a recent live Ask Me Anything (AMA) session, where members brought forward active questions from their GPCR discovery efforts. The AMA format enables careful examination of evolving data — from Schild slope interpretation to probe dependence and kinetic validation — in real time. Through structured lectures, monthly live AMAs, and full replay access, the Corner provides ongoing refinement of pharmacological judgment across the lifespan of a program. The next live AMA will take place: Thursday, February 26th at 12:00 PM EST You are invited to submit questions in advance to: terry@drgpcr.org Distinguishing Orthosteric vs Allosteric Mechanisms in GPCR Drug Discovery Programs Pharmacologists know the pressure of distinguishing between orthosteric and allosteric drug mechanisms—especially when structural data is unavailable. Functional assays can suggest clarity while quietly masking complexity, creating the illusion of competitive antagonism or obscuring subtle allosteric behavior. Misinterpretation does more than delay progress. It can redirect chemistry strategy, distort translational assumptions, and conceal liabilities that emerge only in vivo or in the clinic. What if a seemingly “clean” antagonist profile reflects silent allosteric modulation? What if probe dependence is quietly signaling selective safety implications? Each experimental decision — system sensitivity, assay configuration, kinetic design — carries strategic consequences. In this session, we explored: Strategic frameworks for early discrimination of orthosteric vs allosteric effects Conceptual tools for interpreting Schild plot deviations and probe dependence Operational practices that strengthen GPCR discovery pipelines Operationalizing Allosteric Signatures Early workflows often rely on rapid “one-way” experiments — screens that may reveal allosteric behavior but cannot definitively exclude it. A substantial rightward shift in a dose–response curve is frequently interpreted as competitive antagonism. However, negative allosteric modulators (NAMs) with modest cooperativity can mimic orthosteric competition across wide concentration ranges. The defining distinction is saturation: Saturation defines the allosteric boundary  — additional modulator produces no further shift. Orthosteric antagonists remain theoretically unlimited  — competition continues as concentration increases. Recognizing this difference early prevents mechanistic misclassification. Interpreting Schild Plots — Curves and Slopes Schild analysis remains foundational, but interpretation requires discipline. When a system approaches full allosteric occupancy, the Schild plot curves and the slope falls below unity — signaling that competitive assumptions no longer apply. Key diagnostic considerations: Curved Schild plots suggest occupancy-limited modulation Linear plots with slope ≠ 1 demand investigation  — equilibration time, receptor heterogeneity, or system-level factors must be assessed before mechanistic conclusions are drawn A slope is not merely a fitted parameter. It is a diagnostic signal. Probe Dependence — A Distinctive Allosteric Readout Allosteric systems exhibit probe dependence: the same modulator can shift one agonist thirty-fold and another six-fold. This variability is not noise — it is mechanistic information. Probe dependence reveals hidden selectivity and efficacy shifts It becomes critical in both screening strategy and therapeutic positioning As ligand diversity expands — including peptide agonists and biased ligands — ignoring probe dependence risks overlooking clinically meaningful distinctions. Assay Sensitivity and System Configuration Receptor expression level is a strategic variable. High-expression systems maximize detection sensitivity and can reveal subtle efficacies. Low-expression systems expose whether observed potency reflects intrinsic efficacy or simple binding strength. This “tissue volume control” becomes essential when: Distinguishing affinity-dominant from efficacy-dominant agonists Detecting silent partial agonism Extracting operational model parameters with translational relevance System configuration shapes interpretation. Decoding Kinetics — The Allosteric Differentiator Kinetic experiments provide definitive mechanistic evidence. Only allosteric modulators alter the onset or offset of agonist responses. Demonstrating changes in association or dissociation rates moves analysis beyond functional shifts toward mechanistic proof. Allosterics modify agonist kinetics Orthosteric competitors do not For publication-grade validation and regulatory confidence, kinetic evidence becomes indispensable. Strategic Use of Repurposing and Data Controls Drug repurposing offers reduced uncertainty and extensive prior data. Yet rare adverse effects may only emerge after large-scale exposure, and selectivity must still be demonstrated rigorously. Meanwhile, controls remain non-negotiable. GPCR systems are sensitive and context-dependent. Pathway bias, tissue sensitivity, and system artifacts can distort interpretation if not carefully managed. Robust controls distinguish mechanism from artifact Multipathway analysis reduces false confidence Neglecting these elements invites downstream surprises. Integrating Chemistry and Kinetics Early Biological activity alone does not define a viable series. Chemical tractability, early safety screens (e.g., hERG), ADME properties, and residence time often determine long-term success. Potency can attract attention, but residence time and target engagement kinetics frequently better predict in vivo performance. Strategic discipline means: Screening liabilities early Integrating chemistry insights immediately Avoiding advancement of scaffolds likely to collapse later “Fail early” is not pessimism. It is resource stewardship. Best Habits for Data Quality and Reproducibility Detection assays identify activity; they do not validate therapeutic viability. Repetition without purpose consumes time. Statistical rigor prevents wishful interpretation. Quantitative follow-up studies separate true signal from noise. Advance promising hits into mechanistic evaluation quickly Use statistics to arbitrate interpretation Design assays deliberately Interpretive discipline is the foundation of reproducible pharmacology. Why Terry’s Pharmacology Corner Mechanistic understanding evolves. What appears settled under one experimental condition may require refinement under another. Terry’s Pharmacology Corner provides a structured environment for that evolution: Weekly advanced pharmacology lectures Monthly live AMAs for real-time scientific discussion A continually expanding on-demand archive Sustained exposure to disciplined mechanistic reasoning The value lies not in a single explanation, but in maintaining interpretive rigor as programs mature. Forty years of pharmacological expertise — organized into a year-round learning framework for serious GPCR scientists. Explore the full library ➤

Explore the milestones of Dr. GPCR, from its founding to today’s global community, and discover the journey that’s shaping the future of GPCR science. From Vision to Global Impact What began as a simple idea — to connect GPCR scientists and share knowledge freely — has grown into a global ecosystem driving collaboration, innovation, and discovery. Since 2020, Dr. GPCR has united researchers across disciplines and continents through conversations, summits, and shared milestones. 2020 🌱 The Beginning of a Community Vision & Launch Driven by a simple but powerful idea — to bring GPCR scientists together — Dr. Yamina Berchiche launched the Dr. GPCR Ecosystem , a space designed to break silos, spark collaboration, and open real dialogue across disciplines. Early Initiatives Feb 18, 2020 — The very first podcast episode was recorded. Jun 2020 — The first newsletter went out — to just three people . A small start, but the spark had been lit. Podcast Debut Jul 7, 2020 — The first Dr. GPCR Podcast episode premiered, featuring Dr. Paul Insel from UC San Diego — marking the beginning of hundreds of scientist-to-scientist conversations that would follow. First Summit Sep 14–18, 2020 — The inaugural Dr. GPCR Summit brought together researchers from five continents , with 5 live sessions , 26 pre-recorded talks , and five industry sponsors . A milestone moment that proved the power of community — even in a virtual world. Featured Appearances Aug 2020 — Featured on 17 Minutes of Science with Advancing GPCR Drug Discovery Through Collaboration . Oct 2020 — Presented at ERNEST with Beyond the Lab . Nov 2020 — Invited to the 9th GDR Meeting with Beyond the Lab . 2021 Expanding the Conversation Podcast Milestones Jan 2021 — Episode #26 released featuring Dr. Debbie Hay , University of Otago. Feb 2021 — Episode #27 released featuring Dr. Robert J. Lefkowitz , 2012 Nobel Laureate in Chemistry. 2nd Annual Summit Sep 13–19, 2021 — The 2nd Dr. GPCR Summit expanded the community’s reach and impact, featuring 27 live talks , 10 pre-recorded sessions , and five sponsors . Featured Appearances Jul 2021 — Featured at ECR Transatlantic with From Idea to Ecosystem . Oct 2021 — Featured at ERNEST with Where All GPCRs Are Created Equal . 2022 Building Momentum Podcast Growth May 2022 — Episode #37 released featuring Dr. Sam Hoare , Pharmechanics. May 2022 — Episode #42 released featuring Dr. Randy Hall , Emory University. New Programs Aug 11, 2022 — Virtual Café Series launched, featuring 16 episodes . Sep 20, 2022 — First contributor article published: Therapeutic validation of an orphan G protein‐coupled receptor by Inês Pinheiro . Oct 10–16, 2022 — Hosted the 3rd Annual Dr. GPCR Summit , featuring 34 live talks , 12 poster presentations , one pre-recorded session , and four partners . Dec 9, 2022 — GPCR Weekly News launched — now over 120 editions published . Community Engagement Mar 2022 — Featured at ERNEST with Dr. GPCR Ecosystem 2.0: Collaborating Better . Mar 2022 — Featured at ERNEST with Beyond the Lab . Mar 2022 — Media Partner at GPCR Targeted Drug Discovery Summit . May 2022 — Media Partner at GPCR Retreat . Jul 2022 — Media Partner at GPCR ECI Transatlantic . Nov 2022 — Featured at PhageMed Unige with Leadership Is a Learned Skill . 2023 A Year of Reflection and Growth Podcast Milestones Jan 2023 — Released the Dr. Marc Caron Tribute Episodes ( #100 , #101 & #102 ), featuring over 30 expert guests , including Dr. Kathleen Caron and Dr. Brian Kobilka , 2012 Nobel Laureate in Chemistry. First Symposium May 19, 2023 — Hosted the inaugural Dr. GPCR Symposium , bringing together over 100 attendees and featuring 11 live talks Community Engagement Feb 2023 — Media Partner at GPCR Targeted Drug Discovery Summit . Jun 2023 — Featured Talk Molecular Pharmacology GRC and GRS in Switzerland. Jun 2023 — Hosted Meet the Inoviem Team session. Nov 2023 — Co-organized the 22nd Great Lakes GPCR Retreat 2024 Strengthening Foundations and Expanding Horizons Educational Initiatives Feb 8, 2024 — Launched Dr. GPCR University with the first GPCR Course led by Dr. Terry Kenakin , enrolling 30+ students . Podcast Milestones May 9, 2024 — Episode #150 introduced the Dr. GPCR Team . May 16, 2024 — Episode #151 featured the Dr. GPCR Board . Community Engagement Mar 2024 — Media Partner at 3rd GPCR Targeted Drug Discovery Summit . Apr 2024 — Media Partner at Endocrine and Metabolic GPCRs meeting. Oct 2024 — Co-organized the Adhesion GPCR Workshop in Mexico City, with by 65+ participants . Oct 2024 — Media Partner at Discovery on Target . Non Profit Status Apr 2024 — Officially obtained non-profit organization status . Jul 12, 2024 — Hosted the first Board Meeting . Community Impact & Reach Podcast 180+ episodes 200+ guests 4,500+ hours of interviews 49,000+ plays Community 1,300+ ecosystem members 4 team members 6+ symposiums 15+ virtual café episodes Content 4,500+ GPCR papers categorized 200+ weekly news editions 100+ contributor articles 6 university courses Reach 3,800+ Twitter followers 3,000+ LinkedIn followers 100,000+ site sessions 400+ job listings shared

Fill out the form below and our team will contact you within 48 hours. Our podcast typically follows an interview-style format. Can I reschedule or cancel our meeting? Yes, you can reschedule or cancel our meeting through Calendly. We want to ensure that the discussion is engaging and informative for both our guests and our community

Home Registration Full Agenda Venue Travel Tips Sponsors Special Issue on Adhesion GPCRs OUR SPONSORS Up Abstract Submission Submit your research abstracts following our guidelines to present at the conference